Please provide your email address to receive an email when new articles are posted on . Patients with limited-stage small cell lung cancer with ctDNA positivity after chemotherapy had significant ...

Diagnosed with small-cell lung cancer at 28, Montessa Lee has defied the odds for nearly 20 years, surviving a disease with a ...

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer—the leading cause of cancer deaths worldwide—improved long-term survival overall compared with ...

Maida Mangiameli, 75, has defied the odds by surviving over seven years with small-cell lung cancer—a disease with a ...

or on the link below. Small-cell lung cancer (SCLC) is an aggressive form of lung cancer that displays rapid proliferation and early metastatic potential. It accounts for approximately 15% of lung ...

October brought several updates in the lung cancer field, ranging from notable trial results to patient-centered perspectives ...

The use of immunotherapy in patients with various types of cancer has led to dramatic increases in survival. Increased median ...

Zocilurtatug pelitecan shows promising results as a DLL3-targeted therapy for small cell lung cancer, with high response rates and ongoing trials.

University of Queensland researcher Arutha Kulasinghe studied lung biopsies from the tumours of almost 250 patients with ...

Phase 2 data presented at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting show deep and durable tumor regressions in heavily pre-treated melanoma patients, with a mild safety ...

Patritumab deruxtecan (HER3-DXd; MK-1022) is an investigational HER3-directed antibody-drug conjugate composed of a human immunoglobulin G1 monoclonal antibody to HER3 (patritumab) covalently linked ...

Results from a phase 1/2 clinical trial (NCT05099172) show the safety and efficacy of sevabertinib (BAY2927088) in patients ...